7:45 am

Welcome Coffee & Registration

8:30 am Chair’s Opening Remarks

Advances in Preclinical Oncology Model Utilization

8:40 am Organoids: A Revolutionary New Tool for Drug Screening

  • Rekha Pal Director - Scientific Engagement, Crown Bioscience


• Discover organoids as a more physiologically relevant 3D in vitro model
• Find out why HUB organoids are considered a best-in-class system
• Understand how organoids are revolutionizing oncology drug development
• Learn how patient-derived xenografts (PDX) can be leveraged to develop the largest organoid library for oncology drug discovery

9:10 am Leveraging Preclinical Mouse Models to Understand Cancer Cell Behavior at Secondary Sites & Quantify the Risk of Tumor Metastasis


• Understanding the nature of cancer heterogeneity and how this necessitates personalized therapies
• Conducting predictive analysis to determine tumor aggression and metastatic spread likelihood
• Utilizing multiple syngeneic mouse models to trace the fate of metastatic cells from the primary site to distant organs

9:40 am Patient-Derived Tumor Xenografts in Humanized NSG-SGM3 Mice: A New Immuno-Oncology Platform

  • Dr. James Keck Senior Director, Innovation & Product Development, The Jackson Laboratory


• The addition of 3 human cytokines (GM-CSF, IL-3 & Kit Ligand) into the NSG mouse provide for a more robust myeloid compartment after humanization
• Showcase data on the myeloid engraftment kinetics and show checkpoint inhibitor efficacy against several PDX

10:10 am

Speed Networking


This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the preclinical oncology field and establish meaningful business relationships to pursue for the rest of the conference.

10:40 am

Morning Break

Preclinical Models for Drug Discovery From Drug Discovery to Target Validation

11.15 Identifying Predictive & Prognostic Biomarkers Through Preclinical Modeling of Syngeneic Tumors

Maryland Franklin, Executive Director, Scientific Development, Covance

11.45 Combination of a novel RAF/MEK inhibitor, CH5126766, with the FAK inhibitor defactinib for the treatment of KRAS mutant cancer

Silvia Coma, Associate Director, Verastem Oncology

Preclinical Models for Drug Development From Tox to Safety Profiling

11.15 Characterization of Human Cancer Xenografts in Humanized Mice

Jonathan Rios-Doria, Associate Director, Incyte

12.00 Overcoming Translational Barriers by using the SRG Rat: Case Studies with the OncoRat®

Fallon Noto, Director In Vivo & Oncology Services, Hera BioLabs

12:15 pm Networking Lunch

Preclinical Models for Drug Discovery From Drug Discovery to Target Validation

1.15 High-Throughput Screening for Discovery of Drug Mechanisms

1.45 Modeling the Immune Suppressive Tumor Microenvironment In Vitro for Target Discovery

Silvia Goldoni, Principle Scientist, Novartis Institute for Biomedical Research

2.15 Assessment of Murine Colorectal Cancer by UHF Ultrasound Using 3D Reconstruction & Nonlinear Contrast Imaging

Jessica Freeling, Physiology Core Facility Director, The University of South Dakota

Preclinical Models for Drug Development From Tox to Safety Profiling

1.15 Development of Brain Metastasis Cancer Models from Heavily Treated Patients & Strategies

Kin-Hoe Chow, Associate Director of Center for Patient Derived Models, Dana Farber Cancer Institute

1.45 SubQperior: A Superior Syngeneic Model System to Subcutaneous Tumor Models

Holger Weber, Head of In Vivo, Pharmacology ProQuinase

2.00 Adopting the Appropriate Model for Your Target Therapy

Sangeetha Palakurthi, Vice President, Elstar Therapeutic

2:30 pm Afternoon Break & Poster Session

Harnessing Tumor Models to Overcome Low Translation Outside the Clinic

3:30 pm Assessment of Biologics’ Efficacy Using Preclinical Models Featuring Humanized Immune Checkpoint Models or Stem Cell-Reconstituted Immunodeficient Mice

  • Kader Thiam Vice President - Transgenic Technologies & Director - Business Development, GenOway


• Understanding the breakthrough of immunotherapy for the success of cancer therapy
• Exploring why there are subsets of patients, which do not show robust response to immunotherapy
• Navigating the limitations of immuno-oncology to ensure preclinical models recapitulate the complexity of the etiology of tumors
• Exploring how immune checkpoint models as well humanized as immunodeficient mice can be harnessed to interrogate and model anti-tumor immune response

4:00 pm Multidisciplinary Science Elucidates Drug Resistance in Cancer: Integration of Mathematics & Tumor Models

  • Aaron Goldman Instructor in Medicine and Associate Bioengineer, Harvard Medical School


• Methods to integrate the entirety of the tumor ecosystem to interrogate drug resistance
• Blending ex vivo and in vivo models with computational biology to understand how anti-cancer drugs drive tumor resistance
• Utilizing stochastic, deterministic, systems biology and game theory models to uncover novel biological behavior
• Validating mechanistic biology and confirming efficacy of novel drug combinations, in vivo

4:30 pm Roundtable Discussion: The Revolution of the Biobank – Increase Your Model Translational Success & Decrease the Need for Animal Testing Think Tank Roundtable Sessions


This practical and highly interactive breakout roundtable will join attendees to crowd-source solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly, this is a dedicated opportunity for you to voice your experiences and identify unique solutions.

5:20 pm Chair’s Closing Remarks

5:30 pm

Drinks Reception hosted by Crown Bioscience & Poster Session


Join Crown Bioscience’s drinks reception and poster session to help you connect with your peers in a relaxed atmosphere. Continue scientific discussions following the day 1’s presentations and forge new relationships with your fellows.